ArticleInternational journal of surgery case reports2025
Esophageal carcinosarcoma: A rare case report.
Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEsophageal carcinosarcoma (ECS) is a rare malignant tumor with a polypoid configuration. It is biphasic and composed of epithelial carcinomatous and mesenchymal sarcomatous components. CASE PRESENTATION: We present a 74-year-old Persian woman with a known case of hypertension and chronic renal insufficiency who presented with dysphagia one month ago. On presentation she was oriented, with normal ranged Vital signs. The vital signs were within normal ranges. Her physical examination revealed pale conjunctiva. Gastrointestinal endoscopy showed a 29*25 mm ulcerative polypoid lesion in the distal part of the esophagus which several biopsies were taken. Microscopic examination revealed biphasic mesenchymal and epithelial malignant tumors compatible with carcinosarcoma. DISCUSSION: Dysphagia is the most common symptom of ECS. Immunohistochemistry is the diagnostic gold standard for ECS. The markers for the carcinomatous elements are CEA, EMA, pancreatin, chromogranin A, CD56, and synaptophysin, and for the sarcomatous elements, desmin, p63, vimentin, and smooth muscle/sarcomeric actin.
conclusionECS is a biphasic tumor and the most effective treatment option for ECS is surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.